PEPTIDE CORPUS

Cardiovascular & General; Hormonal & Sexual Health / Cardiovascular

Relaxin

Last updated

Evidence on file2 randomised human trials · 3 human observational studies · 5 citations not yet graded
Strongest sourceNCT00520806: A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the… (randomised human trial)

Dosing on file unverified

48h IV infusion: 10, 30, 100, 250 µg/kg/day; Phase 3: 30 µg/kg/day; 48-h IV infusion: 10, 30, 100, or 250 µg/kg/day

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 10

Not graded

5 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Identity

UniProt
P04808 (RLN2)

Caveat on these identifiers

P04808 is prorelaxin H1 (RLN1); the main circulating human relaxin is relaxin-2 (P04090).

Notes unverified prose

Phase 2/3 (RELAX-AHF, Pre-RELAX-AHF); Phase 2/3 (RELAX-AHF); See Hormonal & Sexual Health

Not on file 8

8 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.